-
Single-cell RNA sequencing identifies endothelial-derived HBEGF as promoting pancreatic beta cell proliferation in mice via the EGFR–Kmt5a–H4K20me pathway Diabetol. (IF 8.4) Pub Date : 2024-12-19 Fengling Lai, Kaixin Zhou, Yingjie Ma, Hao Lv, Weilin Wang, Rundong Wang, Tao Xu, Rong Huang
Aims/hypothesis Pancreatic beta cell mass is dynamically regulated in response to increased physiological and pathological demands. Understanding the mechanisms that control physiological beta cell proliferation could provide valuable insights into novel therapeutic approaches to diabetes. Here, we aimed to analyse the intracellular and extracellular signalling pathways involved in regulating the physiological
-
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes Diabetol. (IF 8.4) Pub Date : 2024-12-19 Melanie R. Shapiro, Erin M. Tallon, Matthew E. Brown, Amanda L. Posgai, Mark A. Clements, Todd M. Brusko
Progress in developing therapies for the maintenance of endogenous insulin secretion in, or the prevention of, type 1 diabetes has been hindered by limited animal models, the length and cost of clinical trials, difficulties in identifying individuals who will progress faster to a clinical diagnosis of type 1 diabetes, and heterogeneous clinical responses in intervention trials. Classic placebo-controlled
-
Bereavement and type 1 diabetes in childhood: a register-based cohort study in Sweden Diabetol. (IF 8.4) Pub Date : 2024-12-19 Mona-Lisa Wernroth, Beatrice Kennedy, Katja Fall, Diem Nguyen, Awad I. Smew, Per-Ola Carlsson, Bodil Svennblad, Catarina Almqvist, Tove Fall
Aims/hypothesis The potential impact of childhood bereavement—a severe psychological stressor—on childhood type 1 diabetes development remains unclear. Here, we aimed to bridge this knowledge gap and assess whether bereavement characteristics influenced any impact. Methods We conducted a register-based cohort study encompassing 3,598,159 children born in Sweden between 1987 and 2020. Childhood bereavement
-
Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress Diabetol. (IF 8.4) Pub Date : 2024-12-18 Wenyue Yin, Suyun Zou, Min Sha, Liangjun Sun, Haoqiang Gong, Can Xiong, Xinyue Huang, Jianan Wang, Yuhan Zhang, Xirui Li, Jin Liang, Xiaoai Chang, Shusen Wang, Dongming Su, Wanhua Guo, Yaqin Zhang, Tijun Wu, Fang Chen
Aims/hypothesis The key pancreatic beta cell transcription factor v-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA) is critical for the maintenance of mature beta cell function and phenotype. The expression levels and/or activities of MafA are reduced when beta cells are chronically exposed to diabetogenic stress, such as hyperglycaemia (i.e. glucotoxicity). Interventional targets and
-
Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study Diabetol. (IF 8.4) Pub Date : 2024-12-18 Vida Bitarafan, Javad Anjom-Shoae, Peyman Rezaie, Penelope C. E. Fitzgerald, Kylie Lange, Michael Horowitz, Christine Feinle-Bisset
Aims/hypothesis Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy people, with consequent implications for the management of type 2 diabetes; the effect of quinine on energy intake is uncertain. We have investigated the dose-related
-
Genetic variation in the RETN promoter, accompanied by latent sarcopenic obesity, led to insulin resistance in a Japanese cohort: the Toon Genome Study Diabetol. (IF 8.4) Pub Date : 2024-12-13 Yosuke Ikeda, Ryoichi Kawamura, Yasuharu Tabara, Koutatsu Maruyama, Daisuke Shiokawa, Misaki Takakado, Toshimi Hadate, Yasunori Takata, Jun Ohashi, Isao Saito, Yoshihiro Ogawa, Haruhiko Osawa
Aims/hypothesis Resistin, inducing insulin resistance, is elevated in the sera of individuals with the G-A haplotype at c.-420 C>G (rs1862513) and c.-358 G>A (rs3219175). This haplotype is associated with visceral obesity and low grip strength. To elucidate the hidden relationship between the G-A haplotype and insulin resistance, integration of specific phenotypes defined by body composition and 75
-
Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes Diabetol. (IF 8.4) Pub Date : 2024-12-13 Maria J. Redondo, David Cuthbertson, Andrea K. Steck, Kevan C. Herold, Richard Oram, Mark Atkinson, Todd M. Brusko, Hemang M. Parikh, Jeffrey P. Krischer, Suna Onengut-Gumuscu, Stephen S. Rich, Jay M. Sosenko
Aims/hypothesis Many studies of type 1 diabetes pathogenesis focus on individuals with high-risk HLA haplotypes. We tested the hypothesis that, among islet autoantibody-positive individuals, lacking HLA-DRB1*04-DQA1*03-DQB1*0302 (HLA-DR4-DQ8) and/or HLA-DRB1*0301-DQA1*0501-DQB1*0201 (HLA-DR3-DQ2) is associated with phenotypic differences, compared with those who have these high-risk HLA haplotypes
-
Elevated risk of infection in individuals with hyperinsulinaemic type 2 diabetes: a Danish 12 year cohort study Diabetol. (IF 8.4) Pub Date : 2024-12-11 Frederik P. B. Kristensen, Sidsel L. Domazet, Jens S. Nielsen, Jacob V. Stidsen, Kurt Højlund, Henning Beck-Nielsen, Peter Vestergaard, Niels Jessen, Michael H. Olsen, Torben Hansen, Charlotte Brøns, Allan Vaag, Henrik T. Sørensen, Reimar W. Thomsen
Aims/hypothesis A better understanding of the mechanisms underlying an elevated infection risk in individuals with type 2 diabetes is needed to guide risk stratification and prevention. We investigated the risk of infection in subgroups of individuals with type 2 diabetes according to indices of insulin sensitivity and beta cell function. Methods We classified 7265 individuals with recently diagnosed
-
Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial Diabetol. (IF 8.4) Pub Date : 2024-12-11 J. David Smeijer, Sieta T. de Vries, Donald E. Kohan, Fan Fan Hou, Hiddo J. L. Heerspink
Aims/hypothesis In the Study Of diabetic Nephropathy with AtRasentan (SONAR), the endothelin receptor antagonist (ERA) atrasentan slowed progression of chronic kidney disease (CKD) in individuals with type 2 diabetes. Pre-clinical research suggests sex-based differences in the endothelin system might influence the efficacy and safety of atrasentan. We therefore assessed the effects of atrasentan in
-
The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) Diabetol. (IF 8.4) Pub Date : 2024-12-10 Othmar Moser, Dessi P. Zaharieva, Peter Adolfsson, Tadej Battelino, Richard M. Bracken, Bruce A. Buckingham, Thomas Danne, Elizabeth A. Davis, Klemen Dovč, Gregory P. Forlenza, Pieter Gillard, Sabine E. Hofer, Roman Hovorka, Peter G. Jacobs, Julia K. Mader, Chantal Mathieu, Kirsten Nørgaard, Nick S. Oliver, David N. O’Neal, John Pemberton, Rémi Rabasa-Lhoret, Jennifer L. Sherr, Harald Sourij, Martin
Regular physical activity and exercise (PA) are cornerstones of diabetes care for individuals with type 1 diabetes. In recent years, the availability of automated insulin delivery (AID) systems has improved the ability of people with type 1 diabetes to achieve the recommended glucose target ranges. PA provide additional health benefits but can cause glucose fluctuations, which challenges current AID
-
Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials Diabetol. (IF 8.4) Pub Date : 2024-12-10 Sieta T. de Vries, Michelle J. Pena, Sok Cin Tye, Sanne A. E. Peters, Daniël H. van Raalte, Clare Arnott, Adriaan A. Voors, Peter G. M. Mol, Petra Denig, Hiddo J. L. Heerspink
Aims/hypothesis Our aim was to assess sex differences in the efficacy of angiotensin receptor blockers (i.e. losartan and irbesartan) on kidney and cardiovascular outcomes in individuals with type 2 diabetes and diabetic kidney disease. Methods Data from the Angiotensin II Antagonist Losartan Study (RENAAL) and Irbesartan type II Diabetic Nephropathy Trial (IDNT) were used. The kidney outcome was time
-
Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function Diabetol. (IF 8.4) Pub Date : 2024-12-05 Matthew E. Brown, Puchong Thirawatananond, Leeana D. Peters, Elizabeth J. Kern, Sonali Vijay, Lindsey K. Sachs, Amanda L. Posgai, Maigan A. Brusko, Melanie R. Shapiro, Clayton E. Mathews, Rhonda Bacher, Todd M. Brusko
Aims/hypothesis Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. There is an outstanding need to augment the durability and effectiveness of T cell targeting therapies by directly restraining proinflammatory T cell subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a
-
A critique of measurement of defective insulin secretion and insulin sensitivity as a precision approach to gestational diabetes Diabetol. (IF 8.4) Pub Date : 2024-12-02 Danielle L. Jones, Laura C. Kusinski, Clare Gillies, Claire L. Meek
Aims/hypothesis Precision medicine approaches to gestational diabetes mellitus (GDM) have categorised patients according to disease pathophysiology (insulin resistance, insulin insufficiency or both), and demonstrated associations with clinical outcomes. We aimed to assess whether using enhanced processing to determine indices of insulin secretion and sensitivity is analytically robust, reproducible
-
The effect of vitamin D3 supplementation on the incidence of type 2 diabetes in healthy older adults not at high risk for diabetes (FIND): a randomised controlled trial Diabetol. (IF 8.4) Pub Date : 2024-12-02 Jyrki K. Virtanen, Sari Hantunen, Niko Kallio, Christel Lamberg-Allardt, JoAnn E. Manson, Tarja Nurmi, Jussi Pihlajamäki, Matti Uusitupa, Ari Voutilainen, Tomi-Pekka Tuomainen
Aims/hypothesis Vitamin D insufficiency is associated with an elevated risk of type 2 diabetes, but evidence from randomised trials on the benefits of vitamin D supplementation is limited, especially for average-risk populations. The Finnish Vitamin D Trial (FIND) investigated the effects of vitamin D3 supplementation at two different doses on the incidence of type 2 diabetes in a generally healthy
-
Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline Diabetol. (IF 8.4) Pub Date : 2024-12-02 Yuqing Chen, Federico Torta, Hiromi W. L. Koh, Peter I. Benke, Resham L. Gurung, Jian-Jun Liu, Keven Ang, Yi-Ming Shao, Gek Cher Chan, Jason Chon-Jun Choo, Jianhong Ching, Jean-Paul Kovalik, Tosha Kalhan, Rajkumar Dorajoo, Chiea Chuen Khor, Yun Li, Wern Ee Tang, Darren E. J. Seah, Charumathi Sabanayagam, Radoslaw M. Sobota, Kavita Venkataraman, Thomas Coffman, Markus R. Wenk, Xueling Sim, Su-Chi Lim
Aims/hypothesis This study aims to explore the association between plasma metabolites and chronic kidney disease progression in individuals with type 2 diabetes. Methods We performed a comprehensive metabolomic analysis in a prospective cohort study of 5144 multi-ancestral individuals with type 2 diabetes in Singapore, using eGFR slope as the primary outcome of kidney function decline. In addition
-
Evidence on the effectiveness and equity of population-based policies to reduce the burden of type 2 diabetes: a narrative review Diabetol. (IF 8.4) Pub Date : 2024-12-02 Joreintje D. Mackenbach, Josine M. Stuber, Joline W. J. Beulens
There is increasing evidence for the effectiveness of population-based policies to reduce the burden of type 2 diabetes. Yet, there are concerns about the equity effects of some policies, whereby socioeconomically disadvantaged populations are not reached or are adversely affected. There is a lack of knowledge on the effectiveness and equity of policies that are both population based (i.e. targeting
-
Postprandial hypoglycaemia after gastric bypass in type 2 diabetes: pathophysiological mechanisms and clinical implications Diabetol. (IF 8.4) Pub Date : 2024-11-29 Domenico Tricò, Luca Sacchetta, Eleni Rebelos, Noemi Cimbalo, Martina Chiriacò, Diego Moriconi, Lorenzo Nesti, Giulia Nesti, Silvia Frascerra, Maria T. Scozzaro, Giuseppe Daniele, Simona Baldi, Andrea Mari, Monica Nannipieri, Andrea Natali
Aims/hypothesis Postprandial hypoglycaemia (PPHG) is a frequent late complication of Roux-en-Y gastric bypass (RYGB) in people without diabetes. We aimed to examine the pathogenetic mechanisms of PPHG and its clinical consequences in people with a history of type 2 diabetes. Methods In this case–control study, 24 participants with type 2 diabetes treated with RYGB (14 women; median [IQR] age 53.5 [13
-
The relationship of changes in insulin demand and insulin adequacy over the life course Diabetol. (IF 8.4) Pub Date : 2024-11-29 Yingchai Zhang, Claudia H. T. Tam, Eric S. H. Lau, Noel Y. H. Ng, Aimin Yang, Baoqi Fan, Hongjiang Wu, Cadmon K. P. Lim, Elaine Y. K. Chow, Andrea O. Y. Luk, Alice P. S. Kong, Wing Hung Tam, Juliana C. N. Chan, Ronald C. W. Ma
Aims/hypothesis Insulin requirements in the human body undergo continuous changes in response to growth and development. We assessed the life course relationships between insulin demand and insulin adequacy. Methods Three independent Chinese cohorts (204 children, aged [mean ± SD] 7.0 ± 0.5 years; 214 adolescents, aged 15.0 ± 1.8 years; 605 adults, aged 41.5 ± 9.3 years), recruited between 1998 and
-
Correction: Quantifying beta cell function in the preclinical stages of type 1 diabetes Diabetol. (IF 8.4) Pub Date : 2024-11-27 Alfonso Galderisi, Alice L. J. Carr, Mariangela Martino, Peter Taylor, Peter Senior, Colin Dayan
-
Diet-enhanced LRG1 expression promotes insulin hypersecretion and ER stress in pancreatic beta cells Diabetol. (IF 8.4) Pub Date : 2024-11-26 Desirae D. Morales, Jiyoon Ryu, Cong Wei, Jason T. Hadley, Maia R. Smith, Juli Bai, Juan C. Lopez-Alvarenga, Srinivas Mummidi, Ravindranath Duggirala, Jane L. Lynch, Feng Liu, Lily Q. Dong
Aims/hypothesis Upregulation of serum leucine-rich α-2-glycoprotein 1 (LRG1) has been implicated in diet-induced obesity and metabolic disorders. However, its specific hormonal actions remain unclear. This study aimed to determine whether diet-enhanced serum LRG1 levels promote hyperinsulinaemia by directly stimulating insulin secretion from pancreatic beta cells. Methods Human serum samples were obtained
-
A polygenic risk score derived from common variants of monogenic diabetes genes is associated with young-onset type 2 diabetes and cardiovascular–kidney complications Diabetol. (IF 8.4) Pub Date : 2024-11-23 Chun-Kwan O, Baoqi Fan, Sandra T. F. Tsoi, Claudia H. T. Tam, Raymond Wan, Eric S. H. Lau, Mai Shi, Cadmon K. P. Lim, Gechang Yu, Jane P. Y. Ho, Elaine Y. K. Chow, Alice P. S. Kong, Risa Ozaki, Wing Yee So, Ronald C. W. Ma, Andrea O. Y. Luk, Juliana C. N. Chan
Aims/hypothesis Monogenic diabetes is caused by rare mutations in genes usually implicated in beta cell biology. Common variants of monogenic diabetes genes (MDG) may jointly influence the risk of young-onset type 2 diabetes (YOD, diagnosed before the age of 40 years) and cardiovascular and kidney events. Methods Using whole-exome sequencing data, we constructed a weighted polygenic risk score (wPRS)
-
Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery in youth and young adults with type 1 diabetes: a randomised controlled two-centre crossover trial Diabetol. (IF 8.4) Pub Date : 2024-11-19 Céline I. Laesser, Camillo Piazza, Nina Schorno, Fabian Nick, Lum Kastrati, Thomas Zueger, Katharine Barnard-Kelly, Malgorzata E. Wilinska, Christos T. Nakas, Roman Hovorka, David Herzig, Daniel Konrad, Lia Bally
Aims/hypothesis The majority of hybrid closed-loop systems still require carbohydrate counting (CC) but the evidence for its justification remains limited. Here, we evaluated glucose control with simplified meal announcement (SMA) vs CC in youth and young adults with type 1 diabetes using the mylife CamAPS FX system. Methods We conducted a two-centre, randomised crossover, non-inferiority trial in
-
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab Diabetol. (IF 8.4) Pub Date : 2024-11-19 Alfonso Galderisi, Emily K. Sims, Carmella Evans-Molina, Alessandra Petrelli, David Cuthbertson, Brandon M. Nathan, Heba M. Ismail, Kevan C. Herold, Antoinette Moran
Aims/hypothesis We aimed to analyse TrialNet Anti-CD3 Prevention (TN10) data using oral minimal model (OMM)-derived indices to characterise the natural history of stage 2 type 1 diabetes in placebo-treated individuals, to describe early metabolic responses to teplizumab and to explore the predictive capacity of OMM measures for disease-free survival rate. Methods OMM-estimated insulin secretion, sensitivity
-
Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes Diabetol. (IF 8.4) Pub Date : 2024-11-12 Gechang Yu, Claudia H. T. Tam, Cadmon K. P. Lim, Mai Shi, Eric S. H. Lau, Risa Ozaki, Heung-man Lee, Alex C. W. Ng, Yong Hou, Baoqi Fan, Chuiguo Huang, Hongjiang Wu, Aimin Yang, Hoi Man Cheung, Ka Fai Lee, Shing Chung Siu, Grace Hui, Chiu Chi Tsang, Kam Piu Lau, Jenny Y. Y. Leung, Elaine Y. N. Cheung, Man Wo Tsang, Grace Kam, Ip Tim Lau, June K. Y. Li, Vincent T. F. Yeung, Emmy Lau, Stanley Lo, Samuel
Aims/hypothesis Type 2 diabetes is a complex and heterogeneous disease and the aetiological components underlying the heterogeneity remain unclear in the Chinese and East Asian population. Therefore, we aimed to investigate whether specific pathophysiological pathways drive the clinical heterogeneity in type 2 diabetes. Methods We employed newly developed type 2 diabetes hard-clustering and soft-clustering
-
The metabolic and circadian signatures of gestational diabetes in the postpartum period characterised using multiple wearable devices Diabetol. (IF 8.4) Pub Date : 2024-11-12 Nicholas E. Phillips, Julie Mareschal, Andrew D. Biancolin, Flore Sinturel, Sylvie Umwali, Stéphanie Blanc, Alexandra Hemmer, Felix Naef, Marcel Salathé, Charna Dibner, Jardena J. Puder, Tinh-Hai Collet
Aims/hypothesis Gestational diabetes mellitus (GDM) affects 14% of all pregnancies worldwide and is associated with cardiometabolic risk. We aimed to exploit high-resolution wearable device time-series data to create a fine-grained physiological characterisation of the postpartum GDM state in free-living conditions, including clinical variables, daily glucose dynamics, food and drink consumption, physical
-
Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes Diabetol. (IF 8.4) Pub Date : 2024-11-12 Mary R. Rooney, Amelia S. Wallace, Justin B. Echouffo Tcheugui, Michael Fang, Jiaqi Hu, Pamela L. Lutsey, Morgan E. Grams, Josef Coresh, Elizabeth Selvin
Aims/hypothesis Prediabetes (HbA1c 39–47 mmol/mol [5.7–6.4%] or fasting glucose 5.6–6.9 mmol/l) is associated with elevated risks of microvascular and macrovascular complications. It is unknown to what extent these risks in prediabetes remain after accounting for progression to diabetes. Methods In 10,310 participants from the Atherosclerosis Risk in Communities (ARIC) Study (aged 46–70 years, ~55%
-
A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome Diabetol. (IF 8.4) Pub Date : 2024-11-09 Raniero Chimienti, Silvia Torchio, Gabriel Siracusano, Valentina Zamarian, Laura Monaco, Marta Tiffany Lombardo, Silvia Pellegrini, Fabio Manenti, Federica Cuozzo, Greta Rossi, Paola Carrera, Valeria Sordi, Vania Broccoli, Riccardo Bonfanti, Giorgio Casari, Giulio Frontino, Lorenzo Piemonti
-
Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 Diabetol. (IF 8.4) Pub Date : 2024-11-08 Eric Wang, Elisabetta Patorno, Farzin Khosrow-Khavar, Stephen Crystal, Chintan V. Dave
-
Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes Diabetol. (IF 8.4) Pub Date : 2024-11-07 Chaitra Rao, Daniel T. Cater, Saptarshi Roy, Jerry Xu, Andre G. De Oliveira, Carmella Evans-Molina, Jon D. Piganelli, Decio L. Eizirik, Raghavendra G. Mirmira, Emily K. Sims
-
NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank Diabetol. (IF 8.4) Pub Date : 2024-11-07 Ronald C. W. Ma, Claudia H. T. Tam, Yong Hou, Eric S. H. Lau, Risa Ozaki, Juliana N. M. Lui, Elaine Chow, Alice P. S. Kong, Chuiguo Huang, Alex C. W. Ng, Erik G. Fung, Andrea O. Y. Luk, Wing Yee So, Cadmon K. P. Lim, Juliana C. N. Chan
-
Increased risk of major adverse cardiovascular events in patients with deep and infected diabetes-related foot ulcers Diabetol. (IF 8.4) Pub Date : 2024-11-07 Nick S. R. Lan, Jonathan Hiew, Ivana Ferreira, J. Carsten Ritter, Laurens Manning, P. Gerry Fegan, Girish Dwivedi, Emma J. Hamilton
-
Diabetes knowledge and behaviour: a cross-sectional study of Jordanian adults Diabetol. (IF 8.4) Pub Date : 2024-11-07 Rula A. Amr, Ahmed M. Al-Smadi, Rand T. Akasheh
-
Transcriptomic heterogeneity of non-beta islet cells is associated with type 2 diabetes development in mouse models Diabetol. (IF 8.4) Pub Date : 2024-11-07 Pascal Gottmann, Thilo Speckmann, Mandy Stadion, Prateek Chawla, Judith Saurenbach, Nikolay Ninov, Heiko Lickert, Annette Schürmann
-
-
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T. Diabetol. (IF 8.4) Pub Date : 2024-11-07 Aikaterini Eleftheriadou,David Riley,Sizheng S Zhao,Philip Austin,Gema Hernández,Gregory Y H Lip,Timothy L Jackson,John P H Wilding,Uazman Alam
-
Frequency and clinical characteristics of children and young people with type 2 diabetes at diagnosis from five world regions between 2012 and 2021: data from the SWEET Registry Diabetol. (IF 8.4) Pub Date : 2024-11-06 Rosaria Gesuita, Alexander J. Eckert, Stéphane Besançon, Nancy A. Crimmins, Fred Cavallo, Jaehyun Kim, Craig Jefferies, Evelien F. Gevers, Anastasios Vamvakis, Sejal Shah, Shazhan Amed, Valentino Cherubini
-
Microvascular insulin resistance with enhanced muscle glucose disposal in CD36 deficiency Diabetol. (IF 8.4) Pub Date : 2024-11-06 Cyndya A. Shibao, Vivek S. Peche, Terri A. Pietka, Dmitri Samovski, Ian M. Williams, Naji N. Abumrad, Eric R. Gamazon, Ira J. Goldberg, David H. Wasserman, Nada A. Abumrad
-
Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity Diabetol. (IF 8.4) Pub Date : 2024-11-04 Daniel T. Meier, Joyce de Paula Souza, Marc Y. Donath
-
Effects of atmospheric pressure change during flight on insulin pump delivery and glycaemic control of pilots with insulin-treated diabetes: an in vitro simulation and a retrospective observational real-world study Diabetol. (IF 8.4) Pub Date : 2024-11-04 Gillian L. Garden, Ka Siu Fan, Megan Paterson, Fariba Shojaee-Moradie, Monique Borg Inguanez, Antonios Manoli, Victoria Edwards, Vivienne Lee, Brian M. Frier, Ewan J. Hutchison, Declan Maher, Chantal Mathieu, Stuart J. Mitchell, Simon R. Heller, Graham A. Roberts, Kenneth M. Shaw, Gerd Koehler, Julia K. Mader, Bruce R. King, David L. Russell-Jones
-
Characterising impaired awareness of hypoglycaemia and associated risks through HypoA-Q: findings from a T1D Exchange cohort Diabetol. (IF 8.4) Pub Date : 2024-10-30 Yu Kuei Lin, Wen Ye, Emily Hepworth, Annika Agni, Austin M. Matus, Anneliese J. Flatt, James A. M. Shaw, Michael R. Rickels, Stephanie A. Amiel, Jane Speight
-
Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial Diabetol. (IF 8.4) Pub Date : 2024-10-30 Pernille E. Hostrup, Tobias Schmidt, Simon B. Hellsten, Rebekka H. Gerwig, Joachim Størling, Jesper Johannesen, Karolina Sulek, Morten Hostrup, Henrik U. Andersen, Karsten Buschard, Yasmin Hamid, Flemming Pociot
-
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications. Diabetol. (IF 8.4) Pub Date : 2024-10-30 Yi-Hsuan Tsai,Nefertiti OjiNjideka Hemphill,Tobias Kurth
-
Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults Diabetol. (IF 8.4) Pub Date : 2024-10-28 Cornelia Santoso, Yuxia Wei, Emma Ahlqvist, Tiinamaija Tuomi, Sofia Carlsson
-
Exposure to antibiotics and risk of latent autoimmune diabetes in adults and type 2 diabetes: results from a Swedish case–control study (ESTRID) and the Norwegian HUNT study Diabetol. (IF 8.4) Pub Date : 2024-10-28 Jessica Edstorp, Marios Rossides, Emma Ahlqvist, Lars Alfredsson, Johan Askling, Daniela Di Giuseppe, Valdemar Grill, Elin P. Sorgjerd, Tiinamaija Tuomi, Bjørn O. Åsvold, Sofia Carlsson
-
The Type 1 Diabetes T Cell Receptor and B Cell Receptor Repository in the AIRR Data Commons: a practical guide for access, use and contributions through the Type 1 Diabetes AIRR Consortium Diabetol. (IF 8.4) Pub Date : 2024-10-29 Stephanie J. Hanna, Rachel H. Bonami, Brian Corrie, Monica Westley, Amanda L. Posgai, Eline T. Luning Prak, Felix Breden, Aaron W. Michels, Todd M. Brusko
-
A modified total body water deficit formula for use in diabetes care. Diabetol. (IF 8.4) Pub Date : 2024-10-29 Philip J G M Voets
-
Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies Diabetol. (IF 8.4) Pub Date : 2024-10-26 David Nathanson, Katarina Eeg-Olofsson, Tim Spelman, Erik Bülow, Mattias Kyhlstedt, Fleur Levrat-Guillen, Jan Bolinder
-
Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes. Diabetol. (IF 8.4) Pub Date : 2024-10-24 Roberto Mallone
-
Molecular mechanisms underlying glucose-dependent insulinotropic polypeptide secretion in human duodenal organoids Diabetol. (IF 8.4) Pub Date : 2024-10-23 Nunzio Guccio, Constanza Alcaino, Emily L. Miedzybrodzka, Marta Santos-Hernández, Christopher A. Smith, Adam Davison, Rula Bany Bakar, Richard G. Kay, Frank Reimann, Fiona M. Gribble
-
GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap. Diabetol. (IF 8.4) Pub Date : 2024-10-21 Felix P Chilunga,George F Mkoma
-
Interactions of genes with alcohol consumption affect insulin sensitivity and beta cell function Diabetol. (IF 8.4) Pub Date : 2024-10-19 Qi Fu, Hao Dai, Sipeng Shen, Yunqiang He, Shuai Zheng, Hemin Jiang, Pan Gu, Min Sun, Xiaowei Zhu, Kuanfeng Xu, Tao Yang
-
The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice Diabetol. (IF 8.4) Pub Date : 2024-10-18 Qian Wang, Megan P. Leask, Kate Lee, Jagdish Jaiswal, Prasanna Kallingappa, Waruni Dissanayake, Chris Puli’uvea, Conor O’Sullivan, Huti Watson, Phillip Wilcox, Rinki Murphy, Troy L. Merry, Peter R. Shepherd
-
Fasting as an intervention to alter the impact of simulated night-shift work on glucose metabolism in healthy adults: a cluster randomised controlled trial Diabetol. (IF 8.4) Pub Date : 2024-10-18 Stephanie Centofanti, Leonie K. Heilbronn, Gary Wittert, Jillian Dorrian, Alison M. Coates, David Kennaway, Charlotte Gupta, Jacqueline M. Stepien, Peter Catcheside, Crystal Yates, Linda Grosser, Raymond W. Matthews, Siobhan Banks
-
Circulating extracellular vesicle-carried PTP1B and PP2A phosphatases as regulators of insulin resistance Diabetol. (IF 8.4) Pub Date : 2024-10-18 Sakina Ali, Xavier Vidal-Gómez, Megan Piquet, Luisa Vergori, Gilles Simard, Séverine Dubois, Pierre-Henri Ducluzeau, Pascal Pomiès, Sarah Kamli-Salino, Mirela Delibégovic, Samir Henni, Frédéric Gagnadoux, Ramaroson Andriantsitohaina, M. Carmen Martínez
-
Quantitative analysis of islet prohormone convertase 1/3 expression in human pancreas donors with diabetes Diabetol. (IF 8.4) Pub Date : 2024-10-15 Paola S. Apaolaza, Yi-Chun Chen, Kavi Grewal, Yannik Lurz, Severin Boulassel, C. Bruce Verchere, Teresa Rodriguez-Calvo
-
Beta cell-specific PAK1 enrichment ameliorates diet-induced glucose intolerance in mice by promoting insulin biogenesis and minimising beta cell apoptosis Diabetol. (IF 8.4) Pub Date : 2024-10-15 Miwon Ahn, Sangeeta Dhawan, Erika M. McCown, Pablo A. Garcia, Supriyo Bhattacharya, Roland Stein, Debbie C. Thurmond
-
Is glycaemic control still central in the hierarchy of priorities in type 2 diabetes management? The way forward is to combine glucose control and the prevention of cardiorenal complications. Diabetol. (IF 8.4) Pub Date : 2024-10-04 Antonio Ceriello,Francesco Prattichizzo,Cesare Berra